BACKGROUND: Cerebrospinal fluid (CSF) lactate levels can be used to differentiate between bacterial and viral meningitis. We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical significance. METHODS: We measured point-of-care CSF lactate at the bedside of 319 Ugandan adults living with human immunodeficiency virus at diagnosis of cryptococcal meningitis. We summarized demographic variables and clinical characteristics by CSF lactate tertiles. We evaluated the association of CSF lactate with clinical characteristics and survival. RESULTS: Individuals with high CSF lactate >5 mmol/L at cryptococcal diagnosis more likely presented with altered mental status (P < .0001), seizures (P = .0005), elevated intracranial opening pressure (P = .03), higher CSF white cells (P = .007), and lower CSF glucose (P = .0003) compared with those with mid-range (3.1 to 5 mmol/L) or low (≤3 mmol/L) CSF lactate levels. Two-week mortality was higher among individuals with high baseline CSF lactate >5 mmol/L (35%; 38 of 109) compared with individuals with mid-range (22%; 25 of 112) or low CSF lactate (9%; 9 of 97; P =<.0001). After multivariate adjustment, CSF lactate >5 mmol/L remained independently associated with excess mortality (adjusted hazard ratio = 3.41; 95% confidence interval, 1.55-7.51; P = .002). We found no correlation between baseline CSF lactate levels and blood capillary lactate levels. CONCLUSIONS: Baseline point-of-care CSF lactate levels are a prognostic marker of disease severity and mortality in cryptococcal meningitis. Individuals with an elevated baseline CSF lactate level are more likely to present with altered mental status, seizures, and elevated CSF opening pressure and are at a greater risk of death. Future studies are needed to determine targeted therapeutic management strategies in persons with high CSF lactate.
BACKGROUND: Cerebrospinal fluid (CSF) lactate levels can be used to differentiate between bacterial and viral meningitis. We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical significance. METHODS: We measured point-of-care CSF lactate at the bedside of 319 Ugandan adults living with human immunodeficiency virus at diagnosis of cryptococcal meningitis. We summarized demographic variables and clinical characteristics by CSF lactate tertiles. We evaluated the association of CSF lactate with clinical characteristics and survival. RESULTS: Individuals with high CSF lactate >5 mmol/L at cryptococcal diagnosis more likely presented with altered mental status (P < .0001), seizures (P = .0005), elevated intracranial opening pressure (P = .03), higher CSF white cells (P = .007), and lower CSF glucose (P = .0003) compared with those with mid-range (3.1 to 5 mmol/L) or low (≤3 mmol/L) CSF lactate levels. Two-week mortality was higher among individuals with high baseline CSF lactate >5 mmol/L (35%; 38 of 109) compared with individuals with mid-range (22%; 25 of 112) or low CSF lactate (9%; 9 of 97; P =<.0001). After multivariate adjustment, CSF lactate >5 mmol/L remained independently associated with excess mortality (adjusted hazard ratio = 3.41; 95% confidence interval, 1.55-7.51; P = .002). We found no correlation between baseline CSF lactate levels and blood capillary lactate levels. CONCLUSIONS: Baseline point-of-care CSF lactate levels are a prognostic marker of disease severity and mortality in cryptococcal meningitis. Individuals with an elevated baseline CSF lactate level are more likely to present with altered mental status, seizures, and elevated CSF opening pressure and are at a greater risk of death. Future studies are needed to determine targeted therapeutic management strategies in persons with high CSF lactate.
Authors: L Tugume; B M Morawski; M Abassi; N C Bahr; R Kiggundu; H W Nabeta; K H Hullsiek; K Taseera; A K Musubire; C Schutz; C Muzoora; D A Williams; M A Rolfes; G Meintjes; J Rhein; D B Meya; D R Boulware Journal: HIV Med Date: 2016-04-28 Impact factor: 3.180
Authors: Fiona V Cresswell; Lillian Tugume; Nathan C Bahr; Richard Kwizera; Ananta S Bangdiwala; Abdu K Musubire; Morris Rutakingirwa; Enock Kagimu; Edwin Nuwagira; Edward Mpoza; Joshua Rhein; Darlisha A Williams; Conrad Muzoora; Daniel Grint; Alison M Elliott; David B Meya; David R Boulware Journal: Lancet Infect Dis Date: 2020-01-07 Impact factor: 71.421
Authors: Fiona V Cresswell; Jayne Ellis; Enock Kagimu; Ananta S Bangdiwala; Michael Okirwoth; Gerald Mugumya; Morris Rutakingirwa; John Kasibante; Carson M Quinn; Kenneth Ssebambulidde; Joshua Rhein; Edwin Nuwagira; Lillian Tugume; Emily Martyn; Caleb P Skipper; Conrad Muzoora; Daniel Grint; David B Meya; Nathan C Bahr; Alison M Elliott; David R Boulware Journal: Open Forum Infect Dis Date: 2020-03-24 Impact factor: 3.835
Authors: Lillian Tugume; Ann Fieberg; Kenneth Ssebambulidde; Edwin Nuwagira; Darlisha A Williams; Edward Mpoza; Morris K Rutakingirwa; Enoch Kagimu; John Kasibante; Laura Nsangi; Samuel Jjunju; Abdu K Musubire; Conrad Muzoora; David S Lawrence; Joshua Rhein; David B Meya; Kathy Huppler Hullsiek; David R Boulware; Mahsa Abassi Journal: Open Forum Infect Dis Date: 2022-06-17 Impact factor: 4.423
Authors: Nathan C Bahr; Fiona V Creswell; Edwin Nuwagira; Kathy Huppler Hullsiek; Samuel Jjunju; Morris Rutakingirwa; John Kasibante; Kiiza Kandole Tadeo; Enock Kagimu; Lillian Tugume; Kenneth Ssebambulidde; Abdu K Musubire; Ananta Bangdiwala; Conrad Muzoora; David B Meya; David R Boulware Journal: Microbiol Spectr Date: 2022-06-21